Adverse event, n (%) | Study cohort (N=20) |
---|---|
Any adverse event | 20 (100) |
Nasopharyngitis | 12 (60) |
Abdominal pain | 11 (55) |
Headache | 11 (55) |
Oropharyngeal pain | 11 (55) |
Fever | 10 (50) |
Diarrhoea | 9 (45) |
Arthralgia | 8 (40) |
Vomiting | 8 (40) |
Fatigue | 7 (35) |
Upper respiratory tract infection | 7 (35) |
Cough | 6 (30) |
Musculoskeletal pain | 6 (30) |
Myalgia | 6 (30) |
Dizziness | 5 (25) |
Rhinitis | 5 (25) |
Abdominal pain upper | 4 (20) |
Bronchitis | 4 (20) |
Condition aggravated | 4 (20) |
Pharyngitis | 4 (20) |
Back pain | 3 (15) |
Chest pain* | 3 (15) |
Cystitis | 3 (15) |
Ear pain | 3 (15) |
Epistaxis | 3 (15) |
Lower respiratory tract infection | 3 (15) |
Pain in extremity | 3 (15) |
Paraesthesia | 3 (15) |
Rash | 3 (15) |
Respiratory tract infection | 3 (15) |
Toothache | 3 (15) |
Viral infection | 3 (15) |
*Of these three events, two were non-cardiac chest pain and the other was related to tumour necrosis factor receptor-associated periodic syndrome (TRAPS) disease activity. None were considered related to canakinumab by the investigator.